You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

 

CPD

Optimizing Bronchodilator Use in COPD

  • Authors: Alan Kaplan, MD, CCFP(EM), FCFP
  • CPD Released: 4/22/2021
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 4/22/2022, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US primary care providers, pulmonologists, and allergists/clinical immunologists.

The goal of this activity is to improve decision making about chronic obstructive pulmonary disease (COPD) based on practical cases of COPD presenting in primary care.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Diagnosis and assessment of patients with COPD presenting in primary care
  • Have greater competence related to
    • Initiation of therapy in line with Global Initiative for Chronic Obstructive Lung Disease (GOLD)/American Thoracic Society (ATS) recommendations
    • Personalizing the treatment of COPD in line with recent guidelines
  • Demonstrate greater confidence in their ability to
    • Select the right inhaler for their patients


Disclosures

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.


Faculty

  • Alan Kaplan, MD, CCFP(EM), FCFP

    Chair
    Family Physician Airways Group of Canada
    Immediate Past-Chairperson
    Respiratory Medicine Special Interest Focus Group
    College of Family Physicians of Canada
    Vice President
    Respiratory Effectiveness Group
    Toronto, Ontario, Canada

    Disclosures

    Disclosure: Alan Kaplan, MD, CCFP(EM), FCFP, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca; Boehringer Ingelheim; Covis; CSL Behring; GlaxoSmithKline; Novartis; Pfizer; Sanofi; Teva; Trudell
    Served as a speaker or a member of a speakers bureau for: AstraZeneca; Boehringer Ingelheim; Covis; GlaxoSmithKline; Merck Frosst; Novartis; Pfizer; Purdue; Teva; Trudel

Editors

  • Gillian Griffith, BA (Mod), MA

    Medical Education Director, WebMD Global, LLC 

    Disclosures

    Disclosure: Gillian Griffith, BA (Mod), MA, has disclosed no relevant financial relationships.

  • Frances McFarland, PhD, MA

    Medical Writer, WebMD Global, LLC 

    Disclosures

    Disclosure: Frances McFarland, PhD, MA, has disclosed no relevant financial relationships.

Content Reviewer

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Stephanie Corder, ND, RN, CHCP, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 1.0 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

Optimizing Bronchodilator Use in COPD

Authors: Alan Kaplan, MD, CCFP(EM), FCFPFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CPD Released: 4/22/2021

Valid for credit through: 4/22/2022, 11:59 PM EST

processing....

Note: The information on the coronavirus outbreak is continually evolving. The content within this activity serves as a historical reference to the information that was available at the time of this publication. We continue to add to the collection of activities on this subject as new information becomes available. In order to facilitate disseminating this educational activity as quickly as possible, the associated slides will be included 1-2 weeks after the activity posting date.

The following cases are modeled on the interactive grand rounds approach. The questions within the activity are designed to test your current knowledge. After each question, you will be able to see whether you answered correctly and read evidence-based information that supports the most appropriate answer choice. The questions are designed to challenge you; you will not be penalized for answering the questions incorrectly. At the end of the activity, there will be a short post-test assessment based on the material presented.

Clinical Case 1: Patient History

Joanne is a 52-year-old account executive who has been smoking since the age of 18. She has hypertension and a history of gastroesophageal reflux disease (GERD). She was diagnosed with asthma 3 months ago and started on a dry powder inhaler (DPI) with a combination of formoterol, a long-acting beta-agonist (LABA), and budesonide, an inhaled corticosteroid (ICS). However, she is still symptomatic. During a telemedicine visit with her general practitioner (GP), she reports that she coughs almost all the time, produces a lot of phlegm, and often wakes up in the middle of the night because of coughing. She also mentions that she is often breathless after climbing stairs and does not go out very often because of her symptoms. When asked about her medication, she complains that she has trouble using the DPI.

Based on her symptoms, the GP suspects that Joanne has chronic obstructive pulmonary disease (COPD), not asthma, and he recommends that Joanne comes to the office for spirometry. Spirometry has only recently resumed, on a limited basis, because the procedure generates aerosols and increases the risk of transmitting COVID-19. However, the GP notes that spirometry is urgent and essential to make a correct diagnosis for Joanne, in line with recent guidance. At her appointment, Joanne's spirometry readings reveal that her forced expiratory volume in 1 second (FEV1) is 1.93 L, or 55% predicted; her forced vital capacity (FVC) is 3.50 L; and her FEV1/FVC ratio is 0.55, which is below the lower limit of normal (LLN) of 70%, with no change post-bronchodilator and with her budesonide/formoterol held for 48 hours.

  • Print